



Biotech Daily

Monday September 7, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX EVEN, BIOTECH DOWN: ACTINOGEN UP 11%; CURVEBEAM DOWN 10%**
- * **PHENOMICS AUSTRALIA UP-TO \$50K MATCHING GRANTS**
- * **S&P INDICES: 6 BIOTECHS PROMOTED, 5 DEMOTED**
- * **RENERVE, RMIT \$499k GRANT FOR NERVE REGENERATION**
- * **CLEVER CULTURE: NOVO NORDISK 2 MORE APAS INDEPENDENCE SYSTEMS**
- * **VITURA ISSUES BUPA BREACH NOTICE**
- * **AROVELLA MANUFACTURES ALA-101 FOR BLOOD CANCERS**
- * **CONNEQT SIGNS BLUEPRINT FOR US PULSE DISTRIBUTION**
- * **EBR WINS ISO13485 CERTIFICATION**
- * **ACTINOGEN PLEADS SCHULTZ TO ASX 19% QUERY; UP 16% MORE**
- * **PERCHERON AGM FOR 75m M-D DR MICHAEL BAKER RSUs**
- * **ECHO IQ REQUESTS 'ECHOSOLV REGULATORY' TRADING HALT**
- * **INTELLIVISION TAKES 17.7% OF CURVEBEAM**
- * **PINNACLE, FIRETRAIL DILUTED TO 5.5% OF CURVEBEAM**
- * **NEURIZON APPOINTS DR CHRIS BREMER CEO ON \$450k PA**
- * **CCO MIKE MATHIAS REPLACES SALUDA CEO BARRY REGAN**
- * **BRENT MOEN REPLACES ANTERIS CFO MATTHEW MCDONNELL**
- * **POLYNOVO: TYSON PARKER MANUFACTURING, SUPPLY CHAIN HEAD**

MARKET REPORT

The Australian stock market edged up 0.06 percent on Monday September 7, 2026, with the ASX200 up 5.0 points to 9,010.9 points. Ten of the Biotech Daily Top 40 companies were up, 21 fell and nine traded unchanged. All four Big Caps fell.

Actinogen was the best, up 0.6 cents or 11.3 percent to 5.9 cents, with 23.2 million shares traded. Starpharma climbed 5.3 percent; Paradigm was up 3.8 percent; EBR, Orthocell, Polynovo and Racura rose one percent or more; with Aroa, Clinuvel and Neuren up by less than one percent.

Curvebeam led the falls, down 0.2 cents or 10.0 percent to 1.8 cents, with 486,379 shares traded. Impedimed lost 9.1 percent; Mesoblast shed 6.3 percent; Atomo and Saluda were down more than five percent; Artrya, Immutep, Lumos and Micro-X fell more than four percent; Pro Medicus, Resonance and Syntara lost more than three percent; 4D Medical and Medical Developments shed more than two percent; Cochlear, Cyclopharm, Dimerix, Imricor, Imugene, Nanosonics and Telix were down more than one percent; with Avita, Clarity, CSL and Resmed down by less than one percent.

PHENOMICS AUSTRALIA

Phenomics Australia says it is offering up to \$50,000 matching grants in its Round 1 vouchers of its Pipeline Accelerator program for 2026-'27.

Phenomics Australia did not say how many grants would be available.

The organization said that applications would close on Friday October 30, 2026.

Phenomics Australia said that the scheme was supported by Microscopy Australia, the Federally-funded Therapeutic Innovation Australia (TIA) of the National Collaborative Research Infrastructure Strategy, the Australian Nuclear Science and Technology Organisation's (ANSTO) National Deuteration Facility and Bioplatforms Australia.

The organization said that the Pipeline Accelerator was "a competitive voucher-style scheme to subsidize the cost of access to Phenomics Australia, TIA, and ANSTO National Deuteration Facility-supported facilities, with optional additional access to Bioplatforms Australia and Microscopy Australia through supplementary vouchers.

"To access a supplementary voucher from Bioplatforms Australia or Microscopy Australia, applicants must also apply for a Phenomics Australia, TIA, and/or NDF voucher in the same application," Phenomics Australia said.

To apply, go to: <https://phenomicsaustralia.org.au/voucher-scheme/>.

STANDARD AND POOR'S DOW JONES INDICES

Standard & Poor's says it has added four biotechnology companies to the ASX300, two to the All Ordinaries, demoting four, and removed Cochlear from the ASX50.

Standard & Poor's said Artrya, Echo IQ, Imricor and PYC had been promoted into the ASX300 with Immutep dropped from both the ASX300 and All Ordinaries Index.

The ratings agency promoted Starpharma and Vitrafy into the All Ordinaries, demoting Botanix, Dimerix, Immutep and Saluda.

Previously, Standard & Poor's told Biotech Daily that inclusion in the indices was based solely on market capitalization.

The Biotech Daily Top 40 Index (BDI-40) is based on quality of science, benefit to human health, board and management, investment potential and market capitalization.

RENERVE

Renerve says with the Royal Melbourne Institute of Technology it has a \$498,856 grant to use patients' blood for nerve regeneration post prostate surgery.

Renerve said that the Federal Education Department grant would be allocated to RMIT and Renerve with and Prof Shadi Houshyar leading the research.

The company said the technology held "potential beyond prostate surgery, with the partnership focused on development of a gel ... in a nerve cuff or wrap, and could be used with additional tissue products like Renerve's nerve conduits and nerve guide matrix".

Renerve said that its Nervalign products were designed to benefit patient recovery and "as platforms for delivery of cell therapies, enriched blood products and similar treatment products that focus on accelerated nerve repair and recovery".

Renerve chief scientific officer Dr David Rhodes said that "being able to accelerate nerve regeneration would greatly benefit surgical outcomes as well as improving outcomes for patients".

The company said the project, 'Universal Platform for Tissue Regeneration and Healing: Addressing Nerve Injury', was at the research and development stage, with no assurance the technology would achieve its intended objectives.

Renerve was unchanged at 7.4 cents.

CLEVER CULTURE SYSTEMS

Clever Culture says it Novo Nordisk has ordered two additional automated plate assessment system (Apas) Independence instruments.

Clever Culture said Novo Nordisk had increased its installed base to three Apas Independence systems including development of an integrated product for Novo Nordisk's Laboratory Information Management System, enabling further expansion of the Apas technology at more Novo Nordisk sites.

Clever Culture managing-director Brent Barnes said the order was "a further demonstration of the Apas technology performance and provides evidence of our long-stated 'Land and Expand' strategy targeting major global pharmaceutical manufacturers".

"Sterile drug manufacturing companies rightly undergo a rigorous process when introducing new technologies into their manufacturing network," Mr Barnes said.

"Patient safety, data integrity and regulatory compliance is critical, and we have designed Apas from the outset to meet these requirements and to integrate into our customers' systems," Mr Barnes said. "Importantly, we are now seeing the early benefits of the customer base we have established over the past two years."

"As these customers progress from evaluation and initial adoption towards broader deployment, we expect expansion from existing customers to become the major driver of a step-change in sales from [2026-'27] and beyond," Mr Barnes said.

Clever Culture said the two instruments would be installed at a single site in Denmark and used to complete a formal validation of the Apas technology.

The company said Novo Nordisk placed an order to start work on an advanced interface between their global Laboratory Information Management System and Apas technology.

Clever Culture said the interface will support a bi-directional communication between LIMS and the Apas instrument to allow for more intelligent sorting of environmental monitoring samples, ultimately driving greater value from the instrument.

Clever Culture rose 0.4 cents or 28.6 percent to 1.8 cents with 3.2 million shares traded.

VITURA HEALTH

Vitura says it has issued London's British United Provident Association (BUPA) "a breach notification" following the insurers' redirection of customers to a competitor.

Vitura said it acquired Doctors on Demand in 2023 as its "24/7 virtual [general practitioner] primary care telehealth service ... [which was] a longstanding contracted partner of BUPA Australia Health Insurance" and renewed annually (BD: Oct 19, 2023).

The company said despite previous indications, BUPA began a pilot program with overseas students using Doctors on Demand automatically directed to another platform.

Vitura said on September 9, 2026, BUPA advised that it would "automatically redirect all international [foreign] members currently serviced by Doctors on Demand (all overseas visitors and students) to Hola Health, an alternative platform in which BUPA holds a beneficial financial interest ... despite prior confirmation in May 2026 from BUPA to Doctors on Demand of its expected increased volume requirements for calendar years 2026 and 2027, on which Doctors on Demand based its resourcing and operating plans".

Vitura said foreign member referrals made-up about 77 percent of Doctors on Demand's total BUPA patients, Doctors on Demand was expecting a \$6 million fall in revenue in 2026-'27; and the remaining 23 percent, being domestic members, were expected to be referred to Doctors on Demand until the end of the contract on December 31, 2026.

"Despite this, Vitura reconfirms its view that the Group's [2026-'27] financial results are expected to be significantly improved on [2025-'26]," the company said.

Vitura fell 0.4 cents or 14.8 percent to 2.3 cents with three million shares traded.

AROVELLA THERAPEUTICS

Arovella says it has manufactured the first clinical batch of ALA-101 for blood cancers and activated Melbourne's Alfred Hospital as the first trial site for its phase I study.

Arovella said that it expected to dose its first patient this month.

The company said that ALA-101 was "a donor-derived cell therapy made in batches from healthy donor cells rather than each patient's own cells" with the potential to be delivered to the patient faster and manufactured at a lower cost than conventional therapies derived from a patient's own blood.

Arovella said that clinical manufacturing was "a critical step toward demonstrating the key advantages of Arovella's platform of off-the-shelf availability, rapid access to treatment, and the potential to overcome many of the manufacturing and cost limitations associated with using a patient's own cells".

Arovella acting chief executive officer Dr Nicole van der Weerden said that the first clinical batch was "a significant achievement and key milestone".

Arovella was up 0.2 cents or 3.3 percent to 6.3 cents.

CONNEQT HEALTH

Conneqt says the Los Angeles-based Blueprint will expand its US consumer distribution network for its Pulse Arterial Health Monitor.

Conneqt said that Blueprint would provide "dedicated referral links and promotional offers" for its US Food and Drug Administration-cleared Pulse Monitor.

The company said that customers referred through Blueprint would buy directly from Conneqt complementing its existing direct-to-consumer strategy "by adding another strategically aligned distribution channel targeting consumers actively engaged in preventative health, longevity and ongoing health optimization".

Conneqt chief executive officer Craig Cooper said that Blueprint had "established a trusted community of consumers focused on evidence-based longevity and preventative health, making Blueprint a natural commercial partner for Conneqt Pulse and our broader cardiovascular health platform".

"This agreement represents another important step in expanding our commercial distribution strategy through trusted health ecosystems," Mr Cooper said.

Conneqt was up 0.4 cents or 23.5 percent to 2.1 cents with 1.1 million shares traded.

EBR SYSTEMS

EBR says that it has been granted International Organization of Standardization (ISO) 13485 certification "a key quality and operational milestone".

EBR said that its Santa Clara, California manufacturing facility had achieved ISO13485 certification following assessment by standards and certification body the British Standards Institute (BSI).

The company said that additional manufacturing equipment had been installed to support the transition from manual to automated assembly, increasing production capacity of the Wise wireless cardiac pacing system by about 500 percent.

EBR said that US Food and Drug Administration pre-approval inspection was scheduled for September 2026 with expected approval this year.

EBR chief executive officer John McCutcheon said that ISO certification was "an important milestone in EBR's manufacturing scaleup strategy".

EBR was up half a cent or 1.8 percent to 28.5 cents with 3.5 million shares traded.

ACTINOGEN

Actinogen has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 18.6 percent from 4.3 cents last Wednesday September 2, 2026, to 5.1 cents on Friday September 4, 2026 and noted a "significant increase" in the trading volume on September 3 and 4, 2026.

Actinogen was up 0.6 cents or 11.3 percent to 5.9 cents with 23.2 million shares traded.

PERCHERON THERAPEUTICS (FORMERLY ANTISENSE THERAPEUTICS)

Percheron will vote to grant managing-director Dr Michael Baker 75,000,000 restricted stock units (RSUs) vesting on achievement of share price targets.

Percheron said that 30,000,000 RSUs would vest on reaching 0.5 cents a share on the 20-day volume-weighted average price within five years, 30,000,000 more at 1.0 cents on the 20-day VWAP and the final 15,000,000 on reaching 1.5 cents at the 20-day VWAP within five years.

The company said that the annual general meeting would vote on the remuneration report, to elect Dr James Garner as a director, Ratify the prior issue of options, re-approve the employee option plan, as well as termination benefits, the 10 percent placement capacity, placement shares and options and related party securities.

The meeting will be held virtually and at Hamilton Locke, Level 10, 161 Collins Street Melbourne on October 7, 2026 at 10am (AEDT).

Percheron was unchanged at 0.5 cents with 11.1 million shares traded.

ECHO IQ

Echo IQ has requested a trading halt "pending a material announcement with regards to its regulatory pathway for Echosolv HF".

Trading will resume on September 9, 2026 or on an earlier announcement.

Echo IQ last traded at \$1.28.

CURVEBEAM

Singapore's Intellivision Holdings Pte Ltd says it has become a substantial shareholder in Curvebeam with 130,000,000 shares or 17.71 percent.

The substantial shareholder notice said Intellivision bought the shares on September 2, 2026 for \$2.6 million or two cents a share.

In July, Curvebeam said it had commitments to raise \$5 million at 2.0 cents a share in a non-underwritten placement, including \$300,000 from chief executive officer Greg Brown, with \$2,050,000 from director Arun Singh, subject to shareholder approval, as well as \$2,650,000 from other institutional investors. (BD: Jul 8, 2026)

Curvebeam fell 0.2 cents or 10.0 percent to 1.8 cents.

CURVEBEAM

Both Firetrail Investments and Pinnacle Investment Management say their 40,682,305 Curvebeam shareholding has been diluted from 6.74 percent to 5.54 percent.

The Brisbane-based companies' secretary, Terence Kwong filed the notices.

NEURIZON THERAPEUTICS

Neurizon says it has appointed Dr Chris Bremer as its chief executive officer on \$450,000 a year, plus incentives, effective from October 1, 2026.

Neurizon said that Dr Bremer had more than 20 years' experience in drug development, portfolio strategy, commercialization and business development, and taking pharmaceutical assets from early development through to product launch and lifecycle management, as well as evaluating and executing transactions.

Neurizon interim executive chair Sergio Duchini said Dr Bremer spent about 20 years with Aachen, Germany's Grünenthal GmbH, rising to interim chief commercial officer, as well as founding Gaiaso Theranostics.

The company said that before his career in medicine and pharmaceuticals, Dr Bremer represented Germany in swimming at the 1992 Olympic Games and captained the German swimming team at the 1996 Olympic Games.

According to his LinkedIn page Dr Bremer held a Doctor of Medicine from Medizinische Hochschule Hannover, a Doctor of Philosophy from the University of Hamburg and a Master of Business Administration from the Institut Européen d'administration des affaires (Insead or the European Institute of Business Administration).

Neurizon said that along with his base salary of \$450,000 a year including superannuation, Dr Bremer was eligible for a short-term incentive of 30 percent of the base salary and a long-term incentive of 100 percent of base salary, with 70 percent in performance rights and 30 percent in options, subject to approvals.

Neurizon was up 0.7 cents or 12.5 percent to 6.3 cents with one million shares traded.

SALUDA MEDICAL

Saluda says that chief commercial officer Mike Mathias has been promoted to replace chief executive officer Barry Regan.

Saluda said that Mr Mathias was appointed chief commercial officer in November 2024 and had "played a pivotal role in the company's ... commercial strategy and execution".

The company said that previously Mr Mathias had more than 30 years healthcare and medical technology experience, including at Medtronic, Limflow and Endologix.

Saluda chair Doug Godshall thanked Mr Regan "for his leadership and contribution".

According to his LinkedIn page, Mr Mathias holds a Bachelor of Science in Arabic and French studies from the US Military Academy at West Point and a Master of Business Administration from the University of Minnesota.

Saluda fell 2.5 cents or 5.8 percent to 40.5 cents.

ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris says it has appointed Brent Moen as its chief financial officer, replacing, Matthew McDonnell who continues as Australian head, from September 11, 2026.

Anteris said Mr Moen was a "financial executive" with more than 25 years' experience, including as a chief financial officer at public and private companies; and had expertise in capital markets, investor relations, mergers and acquisitions, and scaling growth-oriented organizations, including medical technology companies.

The company said Mr Moen was chief financial officer of Lifelens Technologies, Tactile Systems Technology and Entellus Medical.

Anteris said that Mr Moen held a Bachelor of Accountancy from the University of North Dakota.

Anteris was up 20 cents or 1.7 percent to \$12.20.

POLYNOVO

Polynovo says it has appointed Tyson Parker as its chief manufacturing and supply chain officer, from September 7, 2026.

In an email not announced to the ASX, Polynovo said that Mr Parker had pharmaceutical and biotechnology manufacturing experience, most recently with CSL Seqirus.

Polynovo was up one cent or 1.0 percent to \$1.04 with 3.3 million shares traded.